AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT. Pam will succeed David Smith, who is retiring after nearly ten years with AstraZeneca.

Pam will be responsible for manufacturing operations and supply chain, procurement and information technology globally. In the role she will oversee continued progress in driving efficiency and delivering excellence in these areas.

Pam joins AstraZeneca from Merck/MSD, where she gained extensive experience in pharmaceuticals manufacturing and supply chain management. She played a lead role in restructuring and upgrading the company's manufacturing technology and engineering capabilities as Director of Global Planning and Capacity Management, and as Head of Global Supply Chain Management and Logistics led the transformation of the company's supply chains across its global network. Most recently, Pam was Chief Operating Officer and then President of MSD China. Prior to joining Merck, Pam held Process Engineering roles at Union Carbide and GAF Chemicals.

Pascal Soriot, Chief Executive Officer, said: "I am delighted to welcome Pam to AstraZeneca at a very exciting time for our business. As our pipeline delivers, we will bring an increasing number of new medicines to patients across the globe over the coming years, including important biological therapies as our product mix shifts. Pam will be able to bring to bear her wealth of experience in manufacturing and supply chain management, as well as her experience in emerging markets, particularly China, a key priority for our company."

"I also want to take the opportunity to thank David Smith for the invaluable contribution he has made to the leadership of AstraZeneca and to streamlining and expanding our global manufacturing footprint. The quality, reliability and cost effectiveness of our supply chain will be his legacy for many years to come."

Pam will report to Pascal Soriot and will be a member of AstraZeneca's Senior Executive Team.

Pam holds bachelor's and master's degrees in Chemical Engineering from Stevens Institute of Technology in New Jersey and an MBA in Marketing from Pace University in New York.

– ENDS –


To obtain a photograph of Pam Cheng please visit or contact the media team (details below).

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:


Media Enquiries

Esra Erkal-Paler

+44 20 7604 8030Call: +44 20 7604 8030 (UK/Global)

Vanessa Rhodes

+44 20 7604 8037Call: +44 20 7604 8037 (UK/Global)

Ayesha Bharmal

+44 20 7604 8034Call: +44 20 7604 8034 (UK/Global)

Jacob Lund

+46 8 553 260 20 (Sweden)

Michele Meixell

+ 1 302 885 6351 (US)

Investor Enquiries

Thomas Kudsk Larsen

+44 20 7604 8199Call: +44 20 7604 8199  

mob: +44 7818 524185Call: +44 7818 524185

Eugenia Litz

Respiratory, Inflammation and Autoimmunity

+44 20 7604 8233Call: +44 20 7604 8233  

mob: +44 7884 735627Call: +44 7884 735627

Nick Stone

Cardiovascular and Metabolic Disease

+44 17 6326 3994Call: +44 17 6326 3994  

mob: +44 7717 618834Call: +44 7717 618834

Karl Hård


+44 20 7604 8123Call: +44 20 7604 8123

mob: +44 7789 654364Call: +44 7789 654364

Craig Marks

Infection, Neuroscience and Gastrointestinal Disease

+44 20 7604 8591Call: +44 20 7604 8591 

mob: +44 7881 615764Call: +44 7881 615764

Christer Gruvris

+44 20 7604 8126Call: +44 20 7604 8126

mob: +44 7827 836825Call: +44 7827 836825

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.